RecruitingPhase 3NCT06093672

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

Studying Polycythemia vera

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Italfarmaco
Intervention: Givinostat(drug)
Enrollment: 220 target
Eligibility: 18 years · All sexes
Timeline: 2024 – 2026

Study locations (30)

University of Alabama at Birmingham, Birmingham, Alabama, United States
Emad Ibrahim, MD, Inc, Redlands, California, United States
US Oncology Inc, Englewood, Colorado, United States
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
Oncology Associates of Oregon, P.C., Eugene, Oregon, United States
MD Anderson Cancer Center, Houston, Texas, United States
Texas Oncology (Webster) - USOR, Houston, Texas, United States
Texas Oncology-Denison Cancer Center, Sherman, Texas, United States
University of Utah - Huntsman Cancer Institute - PPDS, Salt Lake City, Utah, United States
The James Cancer Hospital and Solove Research Institute, Roanoke, Virginia, United States
VA Puget Sound Health Care System - NAVREF - PPDS, Seattle, Washington, United States
Landesklinikum Wiener Neustadt, Wiener Neustadt, Lower Austria, Austria
+15 more locations on ClinicalTrials.gov

Collaborators

PPD Development, LP

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06093672 on ClinicalTrials.gov

Other trials for Polycythemia vera

Additional recruiting or active studies for the same condition.

See all trials for Polycythemia vera →

← Back to all trials